Phospho-EPHA7 (Y791) Antibody

What is the biological significance of Y791 phosphorylation in EPHA7 receptor function?

Y791 phosphorylation represents a critical regulatory site in the EPHA7 receptor tyrosine kinase that determines its tumor suppressive function. Research has demonstrated that this specific phosphorylation site is located in the kinase domain and is essential for ligand-dependent signaling. When researchers generated EphA7 mutants with a Y791F substitution in the kinase domain, they observed complete loss of receptor phosphorylation, indicating this site is primary for EphA7 activation .

The functional significance of Y791 phosphorylation includes:

• Mediation of tumor growth inhibition in prostate cancer models

• Regulation of cell migration and invasion capabilities

• Induction of apoptosis through caspase-3 activation

• Modulation of PI3K/Akt signaling pathways

Importantly, mutational studies have confirmed that EphA7 variants lacking phosphorylation at Y791 fail to confer these tumor-suppressive functions, demonstrating this site's critical importance in the receptor's biological activity .

How does the EPHA7-ephrinA5 interaction influence receptor phosphorylation at Y791?

The interaction between EPHA7 and its cognate ligand ephrinA5 is crucial for Y791 phosphorylation in a ligand-dependent and cell density-dependent manner. Studies have demonstrated several key aspects of this relationship:

• EphrinA5 forms complexes with EPHA7 that can be detected by co-immunoprecipitation in cell lysates

• The level of phosphorylated EPHA7 increases proportionally with cell density, suggesting contact-dependent activation

• Exogenous ephrinA5-Fc administration further enhances EPHA7 phosphorylation, particularly in cells with low endogenous ephrinA5 expression

• EphrinA5 expression gradually increases with cell density, while EPHA7 expression remains relatively stable

This suggests a mechanism where increasing cell-cell contacts facilitate ephrinA5-EPHA7 interactions at cell boundaries, promoting receptor clustering and subsequent phosphorylation at Y791. Researchers should consider this cell density dependency when designing experiments to study EPHA7 phosphorylation status .

What are the recommended storage conditions for Phospho-EPHA7 (Y791) antibodies?

For optimal preservation of antibody activity:

• Store at -20°C for long-term storage (up to one year)

• For frequent use and short-term storage (up to one month), 4°C is acceptable

• Avoid repeated freeze-thaw cycles as these significantly reduce antibody performance

• Antibodies are typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to maintain stability

When working with the antibody, it's recommended to prepare small aliquots upon receipt to minimize freeze-thaw damage. Some researchers report improved stability by adding protease inhibitors to aliquots if working with samples containing high protease activity.

What are the validated applications for Phospho-EPHA7 (Y791) antibodies?

Commercial Phospho-EPHA7 (Y791) antibodies have been validated primarily for:

Most of these antibodies are rabbit polyclonal antibodies raised against synthetic phosphopeptides spanning the Y791 region. Their reactivity typically includes human, mouse, and rat EPHA7 .

For optimal results, researchers should:

• Validate each new antibody lot with positive controls

• Include non-phosphorylated controls to confirm specificity

• Consider using phosphatase inhibitors during sample preparation

• Optimize blocking conditions to minimize background

How can I validate the specificity of a Phospho-EPHA7 (Y791) antibody?

To ensure your Phospho-EPHA7 (Y791) antibody is specifically detecting the phosphorylated form:

• Phosphatase treatment control: Treat duplicate samples with lambda phosphatase to remove phosphorylation. A specific phospho-antibody will show diminished signal in treated samples.

• Y791F mutant comparison: If possible, compare detection in cells expressing wild-type EPHA7 versus Y791F mutant. Research has shown that Y791F mutations abolish phosphorylation, providing an excellent negative control .

• Stimulation experiments: Compare unstimulated cells with those stimulated with ephrinA5-Fc. Studies demonstrate that ligand stimulation increases Y791 phosphorylation, providing a functional validation .

• Peptide competition: Pre-incubate the antibody with the phosphorylated immunogenic peptide versus non-phosphorylated version. Specific signal should be blocked only by the phospho-peptide.

• Cell density comparison: Since EPHA7 phosphorylation increases with cell density, comparing sparse versus confluent cultures can provide additional validation .

This multi-faceted approach ensures confidence in antibody specificity before proceeding with experimental applications.

What controls should be included when studying EPHA7 phosphorylation in cancer models?

When investigating EPHA7 phosphorylation in cancer research, these controls are essential:

• Expression controls:

  • Cell lines with known EPHA7 expression profiles (positive and negative)

  • Comparison of normal versus tumor tissue from the same origin

• Phosphorylation controls:

  • Cells expressing EPHA7 mutants (Y791F, ΔCyto) as negative controls

  • Ephrin-A5 stimulated versus unstimulated cells

• Biological controls:

  • Benign prostate hyperplasia (BPH) tissues versus prostate cancer specimens

  • Cell density gradients to account for contact-dependent phosphorylation

• Technical controls:

  • Total EPHA7 detection alongside phospho-specific detection

  • Bax/Bcl-2 and p-Akt/Akt ratios as downstream indicators

  • Caspase-3 activity as a functional readout

Studies have demonstrated that phosphorylation of EPHA7 correlates with ephrinA5 expression in human prostate tissues, providing an additional parameter to validate your experimental system .

How is EPHA7 phosphorylation status altered in different cancer types?

EPHA7 phosphorylation exhibits distinct patterns across various cancer types:

In prostate cancer specifically, both EPHA7 and ephrinA5 expression are significantly decreased compared to benign prostate hyperplasia (BPH) or paired normal tissues. Furthermore, the phosphorylation of EPHA7 positively correlates with ephrinA5 expression levels in human prostate tissues, suggesting ligand availability as a determinant of receptor activation status .

What is the relationship between EPHA7 phosphorylation and tumor suppression mechanisms?

EPHA7 phosphorylation at Y791 activates several tumor suppression pathways:

• Apoptosis Induction:

  • Phosphorylated EPHA7 upregulates cleaved caspase-3 protein levels

  • Increases expression of pro-apoptotic Bax protein

  • Reduces expression of anti-apoptotic Bcl-2 protein

• PI3K/Akt Pathway Inhibition:

  • Significantly reduces phosphorylated Akt levels

  • Total Akt levels remain unchanged

  • This inhibition is enhanced by ephrinA5-Fc treatment

• Cell Migration and Invasion Suppression:

  • Decreases scratch migration in wound healing assays

  • Reduces invasion through Matrigel

  • Effects are dependent on Y791 phosphorylation and further enhanced by ephrinA5 stimulation

• Proliferation Inhibition:

  • Slows cell proliferation in vitro

  • Reduces Ki-67 expression in tumor xenografts

  • Decreases tumor volume in vivo

These mechanisms collectively contribute to EPHA7's tumor suppressive function, with Y791 phosphorylation serving as the molecular switch that activates these pathways. Importantly, EPHA7 mutants lacking phosphorylation at Y791 fail to induce these effects, confirming the critical role of this phosphorylation site .

Can Phospho-EPHA7 (Y791) serve as a prognostic biomarker in cancer?

Current evidence supports the potential of Phospho-EPHA7 (Y791) as a prognostic biomarker:

In prostate cancer:

• The ratio of phosphorylated EPHA7 to total EPHA7 shows stronger correlation with clinical outcomes than total EPHA7 alone

• Decreased phosphorylation correlates with higher Gleason scores and advanced TNM staging

• The phosphorylation level positively correlates with ephrinA5 expression in tumor tissues

A study examining receptor tyrosine kinases demonstrated that EPHA7 expression was independently associated with:

• Progression-free survival (hazard ratio = 1.237–4.319)

• Cancer-specific survival (hazard ratio = 1.214–4.558)

For clinical applications, several considerations emerge:

• Combined assessment of EPHA7 phosphorylation status and ephrinA5 expression may provide more accurate prognostication

• Phospho-EPHA7 detection in tissue biopsies requires standardized protocols with appropriate controls

• Prospective studies are needed to validate cutoff values for clinical decision-making

While promising, additional large-scale clinical studies are required to establish Phospho-EPHA7 (Y791) as a routine prognostic biomarker in clinical practice.

How do epigenetic mechanisms regulate EPHA7 expression and subsequent phosphorylation?

Epigenetic regulation plays a crucial role in controlling EPHA7 expression, which directly affects phosphorylation potential:

• DNA Methylation:

  • EPHA7 promoter hypermethylation is observed in multiple cancer types

  • In BMI-1 overexpression models, DNA methylation within intron 1 of the EPHA7 promoter-associated CpG island increases over time

  • Treatment with the demethylating agent AZA can rescue EPHA7 expression

• Histone Modifications:

  • H3K27 trimethylation at the EPHA7 promoter increases with BMI-1 overexpression

  • This repressive histone mark precedes DNA methylation, suggesting a sequential epigenetic silencing mechanism

  • ChIP experiments confirmed increased H3K27me3 levels at EPHA7 regulatory regions

• Polycomb Group Protein Involvement:

  • BMI-1, a Polycomb group protein, acts as a direct transcriptional repressor of EPHA7

  • BMI-1 binds to EPHA7 genomic regions and contributes to chromatin modifications

  • This provides a novel mechanism for EPHA7 silencing in tumors with BMI-1 overexpression

The temporal progression appears to involve initial repression via histone modifications followed by more stable silencing through DNA methylation. Since phosphorylation requires protein expression, these epigenetic mechanisms directly impact the potential for Y791 phosphorylation in cancer cells .

What is the interplay between EPHA7 Y791 phosphorylation and the PI3K/Akt pathway in cancer progression?

The relationship between EPHA7 Y791 phosphorylation and PI3K/Akt signaling reveals sophisticated molecular crosstalk:

• Direct Inhibitory Effect:

  • Phosphorylated EPHA7 significantly reduces Akt phosphorylation levels

  • This effect requires Y791 phosphorylation, as Y791F mutants fail to suppress p-Akt

  • EphrinA5 stimulation enhances this inhibitory effect

• Downstream Consequences:

  • Reduced p-Akt correlates with decreased anti-apoptotic Bcl-2 expression

  • Increased pro-apoptotic Bax expression follows p-Akt reduction

  • Caspase-3 activation occurs downstream of these changes

• Mechanistic Details:

  • The precise molecular intermediates between EPHA7 phosphorylation and PI3K/Akt inhibition remain under investigation

  • Possible mechanisms include phosphatase recruitment, direct interaction with PI3K regulatory subunits, or competitive inhibition of growth factor receptor signaling

  • The effect appears to be specific to Akt phosphorylation, as total Akt levels remain unchanged

• Therapeutic Implications:

  • Restoring EPHA7 expression and phosphorylation could potentially sensitize cancer cells to PI3K/Akt inhibitors

  • Combined targeting of ephrinA5/EPHA7 signaling and PI3K/Akt pathway might offer synergistic effects

  • Pharmacological enhancement of EPHA7 phosphorylation represents a potential therapeutic strategy

This interplay provides a mechanistic explanation for how EPHA7 phosphorylation suppresses tumor growth and promotes apoptosis in prostate cancer and potentially other malignancies .

How does cell density affect EPHA7 Y791 phosphorylation and what are the implications for experimental design?

Cell density significantly impacts EPHA7 Y791 phosphorylation through several mechanisms:

• Quantitative Relationship:

  • EPHA7 phosphorylation increases progressively with higher cell density

  • This effect is observed even with constant total EPHA7 expression levels

• Molecular Basis:

  • EphrinA5 expression gradually increases with cell density

  • More cell-cell contacts enable more ephrinA5-EPHA7 interactions

  • This leads to receptor clustering and enhanced phosphorylation

• Experimental Implications:

  • Cell density must be standardized across experimental groups

  • Experiments conducted at different confluency levels are not directly comparable

  • Time-course studies should account for increasing density effects

  • Exogenous ephrinA5-Fc can partially normalize density-dependent effects

• Recommended Protocols:

  • Document and report cell confluency percentages

  • Consider using cell-counting methods rather than time-based approaches

  • For migration/invasion studies, standardize starting densities

  • Include density gradients as internal controls when feasible

Researchers examining EPHA7 phosphorylation should carefully control cell density to ensure experimental reproducibility, as variations in density can significantly confound results even when total EPHA7 expression remains constant .

Why might I observe inconsistent Phospho-EPHA7 (Y791) detection in my samples?

Inconsistent detection of Phospho-EPHA7 (Y791) can arise from multiple factors:

• Sample Preparation Issues:

  • Insufficient phosphatase inhibitors in lysis buffers

  • Delayed sample processing allowing post-lysis dephosphorylation

  • Protein degradation during extraction (add protease inhibitors)

  • Inadequate denaturation before gel loading for Western blot

• Cell Density Variations:

  • Research demonstrates EPHA7 phosphorylation increases with cell density

  • Inconsistent confluence levels between samples can cause variable phosphorylation

  • Even short-term differences in culture conditions can affect results

• Ligand Availability:

  • Variation in endogenous ephrinA5 expression between samples

  • Cell culture medium composition affecting ligand stability

  • Consider standardizing with exogenous ephrinA5-Fc treatment

• Antibody-Related Factors:

  • Lot-to-lot variations in commercial antibodies

  • Inadequate blocking leading to high background

  • Suboptimal antibody dilution for your specific application

  • Secondary antibody cross-reactivity

• Detection System Limitations:

  • Low expression levels requiring more sensitive detection methods

  • Signal saturation masking differences at high expression levels

  • Consider using enhanced chemiluminescence or fluorescence-based detection

For more consistent results, standardize cell density, use freshly prepared lysis buffers with phosphatase inhibitors, optimize antibody dilutions for each new lot, and include appropriate positive and negative controls in each experiment.

What are the optimal dilutions and conditions for detecting Phospho-EPHA7 (Y791) in different applications?

Optimizing detection conditions for different applications:

Western Blot:

• Starting dilution range: 1:500-1:2000

• Recommended blocking: 5% BSA in TBST (phospho-epitopes often bind poorly in milk)

• Incubation: Overnight at 4°C for primary antibody

• Sample loading: 20-50 μg total protein per lane

• Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

ELISA:

• Recommended dilution: 1:10000

• Coating buffer: Carbonate/bicarbonate (pH 9.6)

• Blocking: 1-3% BSA in PBS

• Sample preparation: Similar phosphatase inhibitors as for Western blotting

Optimization Strategy:

• Perform a dilution series (e.g., 1:500, 1:1000, 1:2000) with a positive control sample

• Select the dilution providing best signal-to-noise ratio

• Validate specificity with a Y791F mutant or phosphatase-treated control if available

• For each new antibody lot, repeat optimization with reference samples

When detecting endogenous EPHA7 phosphorylation in cells with low expression (like PC-3), immunoprecipitation prior to Western blotting may improve sensitivity, as standard immunoprecipitation showed limitations in detecting very low EPHA7 levels .

How can phosphorylated EPHA7 be effectively detected in clinical tissue samples?

Detecting phosphorylated EPHA7 in clinical tissues presents unique challenges requiring specialized approaches:

• Sample Collection and Processing:

  • Rapid fixation is critical (within 20 minutes of resection)

  • Phosphorylation can diminish quickly post-resection

  • Phosphatase inhibitors should be incorporated in collection media

  • Consider using phospho-preservation fixatives like Biocare's Phospho-PRESERV™

• Immunohistochemistry Optimization:

  • Antigen retrieval is critical: EDTA buffer (pH 9.0) often works better than citrate for phospho-epitopes

  • Signal amplification systems may be necessary for low abundance targets

  • Positive controls should include tissues with known high phospho-EPHA7 expression

  • Block endogenous peroxidase and biotin to reduce background

• Detection Enhancement Methods:

  • Tyramide signal amplification can increase sensitivity 10-100 fold

  • Polymer-based detection systems generally outperform avidin-biotin methods

  • Multiplex immunofluorescence allows co-localization with total EPHA7 or cell-type markers

  • Automated platforms provide more consistent results across samples

• Validation and Quantification:

  • Compare with parallel Western blot of frozen tissue aliquots when possible

  • Use digital image analysis for quantification rather than manual scoring

  • Calculate phospho-EPHA7 to total EPHA7 ratio for more meaningful results

  • Consider spatial distribution - membrane localization may be more relevant than cytoplasmic

Studies comparing benign prostate hyperplasia (BPH) with prostate cancer specimens have successfully demonstrated differential phospho-EPHA7 patterns using these techniques, with reduced phosphorylation correlating with cancer progression .

What are the emerging therapeutic applications targeting EPHA7 phosphorylation?

Several promising therapeutic approaches targeting EPHA7 phosphorylation are emerging:

• Phosphorylation Enhancement Strategies:

  • Recombinant ephrinA5-Fc fusion proteins to stimulate EPHA7 phosphorylation

  • Small molecules that stabilize ephrinA5-EPHA7 interaction

  • Inhibitors of phosphatases targeting Y791

  • These approaches could restore tumor suppressive functions in cancers with intact but underphosphorylated EPHA7

• Epigenetic Modification Approaches:

  • DNA demethylating agents (like 5-azacytidine) to reverse EPHA7 silencing

  • Histone deacetylase inhibitors to enhance EPHA7 expression

  • BMI-1 inhibitors to prevent EPHA7 repression

  • These could restore EPHA7 expression in tumors where the gene is epigenetically silenced

• Combination Therapies:

  • EPHA7 phosphorylation modulators with PI3K/Akt inhibitors

  • Integration with conventional chemotherapeutics to enhance apoptosis

  • Immunotherapy adjuvants based on EPHA7's role in tumor microenvironment

• Targeted Delivery Systems:

  • Development of EPHA7-targeted nanoparticles for drug delivery

  • Antibody-drug conjugates targeting cells with differential EPHA7 expression patterns

  • Chimeric antigen receptor (CAR) designs incorporating EPHA7-binding domains

These strategies hold potential for precision medicine approaches in cancers where EPHA7 phosphorylation status has prognostic significance, particularly prostate cancer and lymphomas where EPHA7's tumor suppressive role has been established .

How might phospho-specific EPHA7 antibodies be utilized in high-throughput screening applications?

Phospho-specific EPHA7 antibodies enable several high-throughput screening applications:

• Drug Discovery Platforms:

  • Screening compound libraries for molecules that enhance EPHA7 Y791 phosphorylation

  • Identifying inhibitors of phosphatases targeting EPHA7

  • Discovering epigenetic modulators that restore EPHA7 expression

  • Automated ELISA or In-Cell Western approaches can test thousands of compounds

• Tissue Microarray Analysis:

  • Evaluating phospho-EPHA7 levels across large patient cohorts

  • Correlating with clinical outcomes and other molecular markers

  • Determining cut-off values for potential diagnostic applications

  • Digital pathology platforms enable quantitative analysis of thousands of tissue cores

• Multiplexed Phosphorylation Profiling:

  • Simultaneous assessment of EPHA7 and other RTK phosphorylation states

  • Reverse phase protein arrays for studying phosphorylation networks

  • Mass cytometry (CyTOF) with phospho-specific antibodies for single-cell analysis

  • These approaches reveal signaling network relationships

• CRISPR-Based Functional Genomics:

  • Screening gene knockouts that affect EPHA7 phosphorylation status

  • Identifying novel regulators in the EPHA7 phosphorylation pathway

  • High-content imaging with phospho-specific antibodies following genome-wide CRISPR screens

Such high-throughput applications could accelerate understanding of EPHA7 regulation and identify novel therapeutic approaches for cancers where EPHA7 phosphorylation is dysregulated, particularly prostate cancer and lymphomas .

What are the technical limitations in current Phospho-EPHA7 (Y791) detection methods?

Current Phospho-EPHA7 (Y791) detection methods face several limitations:

• Antibody-Related Challenges:

  • Most available antibodies are polyclonal, leading to batch-to-batch variability

  • Limited validation across different applications (most validated only for WB and ELISA)

  • Potential cross-reactivity with other phosphorylated EPH family members

  • Few monoclonal options available for standardized detection

• Sample Preparation Issues:

  • Rapid dephosphorylation during sample processing

  • Phosphatase activity in tissues can vary significantly between samples

  • Low abundance of phosphorylated versus total EPHA7 in many samples

  • Studies note difficulty detecting endogenous phospho-EPHA7 in low-expressing cell lines

• Quantification Challenges:

  • Establishing appropriate normalization methods (total EPHA7 vs. housekeeping proteins)

  • Defining threshold values for "high" versus "low" phosphorylation

  • Accounting for heterogeneous expression within tissues

  • Limited dynamic range of some detection methods

• Technical Gaps:

  • Few validated antibodies for flow cytometry or immunofluorescence applications

  • Limited mass spectrometry protocols for direct phosphorylation site mapping

  • Need for better multiplexed detection methods to assess multiple phosphorylation sites

  • Lack of standardized protocols across laboratories

Research addressing these limitations could significantly advance our understanding of EPHA7 phosphorylation in normal physiology and disease, particularly in cancer contexts where phosphorylation status appears to correlate with tumor suppressive functions .

What are the recommended best practices for studying EPHA7 phosphorylation in cancer research?

Based on current evidence, researchers studying EPHA7 phosphorylation should follow these recommendations:

• Experimental Design:

  • Standardize cell density across experiments (EPHA7 phosphorylation is density-dependent)

  • Include both phospho-specific and total EPHA7 detection for proper interpretation

  • Consider manipulating ephrinA5 levels (using recombinant ephrinA5-Fc) to normalize activation

  • Include Y791F mutant controls when possible for antibody validation

• Technical Considerations:

  • Use fresh lysis buffers with phosphatase inhibitors to prevent post-lysis dephosphorylation

  • Optimize antibody dilutions for each application and new antibody lot

  • Use BSA rather than milk for blocking in phospho-specific Western blots

  • Consider immunoprecipitation followed by Western blotting for low abundance samples

• Data Interpretation:

  • Express phospho-EPHA7 relative to total EPHA7 when possible

  • Consider cell context (particularly cell density and ephrinA5 expression)

  • Examine downstream signaling (p-Akt, Bcl-2/Bax ratio, caspase-3) to confirm functional relevance

  • Account for potential epigenetic regulation of total EPHA7 expression

• Translational Applications:

  • Compare tumor samples with matched normal tissue from the same patient

  • Consider both the phosphorylation status and the expression level of ephrinA5

  • For prognostic studies, correlate with established clinical parameters (Gleason score, TNM staging)

  • Assess potential relationship with other RTKs like c-Met for comprehensive profiling

These practices will enhance data quality and reproducibility in studies investigating the tumor suppressive role of phosphorylated EPHA7 in cancer.

What are the most promising future directions for EPHA7 phosphorylation research?

The most promising future research directions include:

• Mechanistic Studies:

  • Detailed mapping of signaling networks downstream of Y791 phosphorylation

  • Structural studies of phosphorylated versus non-phosphorylated EPHA7

  • Identification of phosphatases that regulate Y791 phosphorylation

  • Investigation of other phosphorylation sites in EPHA7 and their functional interactions

• Clinical Applications:

  • Development of more sensitive phospho-EPHA7 detection methods for clinical samples

  • Prospective studies validating phospho-EPHA7 as a prognostic or predictive biomarker

  • Testing therapeutic strategies that restore EPHA7 phosphorylation

  • Integration with precision medicine approaches based on molecular profiling

• Technological Innovations:

  • Development of monoclonal antibodies with improved specificity and sensitivity

  • Advanced imaging techniques to visualize EPHA7 phosphorylation in live cells

  • Phospho-proteomics approaches to study global effects of EPHA7 activation

  • CRISPR-based screening to identify novel regulators of EPHA7 phosphorylation

• Tumor Microenvironment:

  • Studying how stromal ephrinA5 affects tumor cell EPHA7 phosphorylation

  • Investigating immune cell interactions with tumor cells expressing phosphorylated EPHA7

  • Examining how EPHA7 phosphorylation affects tumor angiogenesis

  • Development of tumor microenvironment models that preserve ephrin-EPH interactions